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INTRODUCTION
It is often difficult to cure metastatic breast cancer 
and recurrent breast cancer, except for some local re-
currences. Thus, the objectives of treatment are im-
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SUMMARY
We present a case of advanced, life-threatening breast cancer with carcinomatous lymphangitis treated 
with bevacizumab plus paclitaxel. A positive therapeutic response was achieved and the treatment was sub-
sequently changed to hormone therapy.
The patient was a 53-year-old postmenopausal woman with a non-contributory medical history. She pre-
sented to a nearby hospital with chief complaints of continued exertional dyspnea and coughing since March 
2012. Physical findings included a palpable mass in the left breast, and the patient was referred and pre-
sented to our hospital in May. Examinations at our hospital revealed left-sided breast cancer （estrogen re-
ceptor positive, progesterone receptor positive, and no amplification of the human epidermal growth factor 
receptor 2 by FISH）. The patient had bone metastasis and carcinomatous lymphangitis （cT2N3cM1-stage 
IV）. The condition was life threatening, and administration of bevacizumab plus weekly paclitaxel was initi-
ated with the expectation of a high response rate. Coughing and dyspnea resolved two weeks later. CT 
scans were taken in August after the completion of 3 cycles and showed improvement in carcinomatous 
lymphangitis. No major side effects were observed due to bevacizumab plus weekly paclitaxel. When the 
CT scans were taken in December after the completion of 6 cycles, the primary lesion and lymph node me-
tastases were reduced in size. In the lung field, there was no thickening of the interlobular septa or subpleu-
ral interstitium, and the findings of carcinomatous lymphangitis were improved. Thus, bevacizumab plus pa-
clitaxel were discontinued and the treatment was changed to oral letrozole （2.5 mg/day）. The patient has 
been followed up with no recurrence as of March 2013.
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sponse was achieved and the therapy was subse-
quently changed to hormone therapy.
CASE REPORT
The patient was a 53-year-old postmenopausal 
woman with a non-contributory medical history. She 
presented to a nearby hospital with chief complaints of 
continued exertional dyspnea and coughing since 
March 2012 . Physical findings included a palpable 
mass in the left breast, and the patient was referred 
and presented to our hospital in May. In the physical 
examination, an elastic, hard mass of 5 cm in size was 
palpated in the left superior-lateral breast. At the 
same location, mammography revealed a high-density 
mass with spicules. Needle biopsy revealed infiltrating 
ductal carcinoma. The biopsy specimen showed a Ki-
67 labeling index of 50％ and was estrogen receptor 
positive, progesterone receptor positive, and without 
amplification of the human epidermal growth factor re-
ceptor 2 by FISH.
provement of QOL and extension of survival as for 
metastatic breast cancer and recurrent breast cancer. 
Carcinomatous lymphangitis is a life-threatening con-
dition. When breast cancer patients also have carcino-
matous lymphangitis, prognosis is very poor if good 
therapeutic effect is not achieved.
Bevacizumab is a humanized monoclonal antibody 
that targets vascular endothelial growth factor 
（VEGF）, a major regulator involved in angiogenesis. 
In Japan, its indications are colon cancer and lung can-
cer and have been expanded to include breast cancer 
in September 2011. Addition of bevacizumab to pacli-
taxel therapy has been shown to significantly extend 
disease-free survival. However, the bevacizumab addi-
tion has not affected overall survival1,2,3）. Thus, there is 
still controversy on the type of patients in whom beva-
cizumab should be used.
This report describes a case of advanced breast can-
cer and carcinomatous lymphangitis treated with beva-
cizumab plus paclitaxel. A positive therapeutic re-
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Figs. 1　A, B, and C （CT in June 2012）
The primary lesion was 4.6×2.0 cm in size at the initial 
examination, and left axillary and supraclavicular lymph 
nodes were enlarged. In the lung field, there was diffuse 
thickening of the interlobular septa and nodular and beaded 
thickening of the subpleural interstitium. The diagnosis of 
carcinomatous lymphangitis was made.
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A case of breast cancer treated with bevacizumab plus paclitaxel
observed due to bevacizumab plus weekly paclitaxel. 
When the CT scans were taken in December after the 
completion of 6 cycles, the primary lesion and lymph 
node metastases were reduced in size. In the lung 
field, there was no thickening of the interlobular septa 
or subpleural interstitium, and the findings of carcino-
matous lymphangitis were improved. Thus, the patient 
was determined to have a PR per the RECIST criteria 
（Figs. 2A, B, and C）. The tumor marker levels de-
creased after initiation of bevacizumab plus weekly pa-
clitaxel. The levels normalized after the completion of 
4 cycles （Fig. 3）.
The life-threatening condition had improved and the 
disease was stabilized. Thus, bevacizumab plus pacli-
taxel were discontinued and the treatment was 
changed to oral letrozole （2.5 mg/day）. Thereafter the 
patient has been followed up without clinical exacerba-
tion as of March 2013.
DISCUSSION
Tumor growth requires oxygen and nutrients. Tu-
mor vessels are needed to supply sufficient oxygen 
CT scans revealed a primary lesion of 4.6×2.0 cm in 
size, and enlargement of the left axillary lymph nodes 
and supraclavicular lymph nodes. In the lung field, 
there was diffuse thickening of the interlobular septa 
and nodular and beaded thickening of the subpleural 
interstitium. The diagnosis of carcinomatous lymphan-
gitis was made （Figs. 1A, B, and C）. Bone scintigraphy 
showed uptake in the spine, ribs, pelvis, and left femur 
（cT2N3cM1-stage IV）. The condition was determined 
to be life threatening because there was carcinomatous 
lymphangitis with coughing and dyspnea. In June, ad-
ministration of bevacizumab plus weekly paclitaxel 
（PTX） （PTX：90 mg/m2, 3 weeks on and 1 week off 
and bevacizumab：10 mg/kg, every 2 weeks） was be-
gun with the expectation of a high response rate. In 
addition, administration of zoledronic acid hydrate 
（4 mg/day, every 4 weeks） was begun for bone metas-
tases. Coughing and dyspnea were resolved two weeks 
after beginning bevacizumab and paclitaxel adminis-
tration. CT scans were taken in August after the com-
pletion of 3 cycles and showed improvement in carci-
nomatous lymphangitis. No major side effects were 
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Figs. 2　A, B, and C （CT in December 2012）
The primary lesion was reduced in size at 3.2×1.3 cm after 
six cycles of bevacizumab plus weekly paclitaxel. The left 
axillary and supraclavicular lymph nodes were also reduced 
in size. In the lung field, there was no thickening of the 
interlobular septa or subpleural interstitium, and the 
findings of carcinomatous lymphangitis were improved.
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0 .001）1）. In the U.S., bevacizumab was promptly ap-
proved for metastatic breast cancer in February 2008 
based on these results. In Japan, its indications were 
expanded to include breast cancer patients in Septem-
ber 2011.
When additional trials were conducted （AVADO 
and RIBBON-1 trials）, the results showed that the 
progression-free survival was prolonged and the re-
sponse rate increased. However, the overall survival 
was not prolonged. In addition, the results suggested 
that the risks for adverse events could outweigh the 
benefits2,3）. In November 2011, the Food and Drug Ad-
ministration （FDA） revoked the approval of bevaci-
zumab for breast cancer. Currently, there is still con-
troversy on the type of patients in whom bevacizumab 
should be used, and it is necessary to thoroughly ex-
amine the risks and benefits before its use.
Carcinomatous lymphangitis is a form of lung metas-
tasis from malignant tumor. It is a condition in which 
embolism of cancer cells occurs due to their infiltration 
into the intrapulmonary lymphatic vessels. The prog-
nosis is poor, with less than half the patients surviving 
past 3 months of the first respiratory symptoms11,12）. 
In recent years, patients with long term survival have 
been reported with advancement in treatment. Al-
though not breast cancer cases, there have been re-
ported cases of carcinomatous lymphangitis secondary 
to colorectal cancer in which long-term survival of 16 
months was achieved using bevacizumab plus mFOL-
FOX6 as the initial treatment13）.
and nutrients as the tumor size increases. Therefore, 
angiogenesis plays an important role in tumor growth 
and metastasis. VEGF is a major regulator involved in 
tumor angiogenesis, growth, and metastasis. It acts as 
a ligand and binds to VEGF receptors on the endothe-
lial cell surface4〜6）.
The molecularly-targeted drug bevacizumab （Avas-
tin；Genentech, South San Francisco, CA） selectively 
binds to a VEGF family member, VEGF-A. Bevaci-
zumab inhibits binding of VEGF-A to VEGF receptors 
（VEGFR-1, VEGFR-2, and neuropilin 1） expressed on 
endothelial cells, thereby blocking the signal transduc-
tion pathway. It inhibits angiogenesis in tumor tissue 
and suppresses tumor growth as a result7）. In addition, 
it has been shown to normalize the vascular structure, 
decrease vascular permeability, and lower increased 
tumor interstitial pressure8,9）. When the tumor intersti-
tial pressure is reduced by bevacizumab, paclitaxel de-
livery to the tumor tissue is improved. Thus, the drug 
concentration increases in the tumor tissue10）.
In 2007, there was a report on a phase III random-
ized trial （E2100） which compared paclitaxel plus be-
vacizumab and paclitaxel alone as initial chemotherapy 
for patients with untreated advanced and recurrent 
breast cancer （n＝722）. The overall survival was not 
significantly prolonged （median：26.7 months vs 25.2 
months, respectively, HR：0.88 , p＝0.16）. However, 
the median progression-free survival was prolonged 
（11.8 months vs 5.9 months, HR：0.60, p＜0.001） and 
the response rate increased （36 .9％ vs 21 .2％, p＜
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Fig.3
The tumor marker levels decreased after initiation of bevacizumab plus 
weekly paclitaxel. The levels normalized after the completion of 4 cycles.
A case of breast cancer treated with bevacizumab plus paclitaxel
The patient of the present report had symptomatic 
carcinomatous lymphangitis. The condition was life 
threatening. Administration of bevacizumab plus 
weekly paclitaxel was initiated, and the patient 
achieved a positive therapeutic response. Thus, the 
treatment was changed to hormone therapy. High re-
sponse rates can be obtained when bevacizumab is 
used in combination with another chemotherapeutic 
agent. Thus, bevacizumab is currently considered a 
drug with major benefits, particularly in patients with 
life-threatening metastasis as in the patient of this re-
port.
In Japan, it has not been very long since bevacizum-
ab has been indicated for metastatic and recurrent 
breast cancer. Since it has not been shown to prolong 
survival, its blind use is also not recommended from 
the aspect of health economics 14）. However, bevaci-
zumab has been shown to achieve a high response 
rate and to prolong progression-free survival. Thus, it 
could be very beneficial depending on the case.
CONCLUSION
We presented a case of advanced, life-threatening 
breast cancer with carcinomatous lymphangitis treated 
with bevacizumab plus paclitaxel. A positive therapeu-
tic response was achieved and the therapy was subse-
quently changed to hormone therapy. In the future, 
more cases need to be accumulated to identify a sub-
set of advanced and recurrent cancer patients in 
which bevacizumab will be more effective.
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